Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

163.16USD
19 Jul 2019
Change (% chg)

$1.11 (+0.68%)
Prev Close
$162.05
Open
$162.46
Day's High
$163.18
Day's Low
$161.01
Volume
493,468
Avg. Vol
679,414
52-wk High
$197.00
52-wk Low
$114.27

Latest Key Developments (Source: Significant Developments)

Elliott management advocated for an Allergan split prior to sale - Bloomberg Reporter Tweet
Wednesday, 26 Jun 2019 

June 26 (Reuters) - :ELLIOTT HAD BUILT STAKE IN ALLERGAN WAS ADVOCATING FOR BREAK UP OF CO PRIOR TO IT ANNOUNCING PLANS TO BE ACQUIRED BY ABBVIE - BLOOMBERG REPORTER TWEET.  Full Article

AbbVie Believes It Is Unlikely There Will Be A Botox Biosimilar For A Long Time - Conf. Call
Tuesday, 25 Jun 2019 

June 25 (Reuters) - AbbVie Inc ::ABBVIE INC EXECUTIVE SAYS ASSETS OF THE QUALITY OF ALLERGAN ARE NOT ALWAYS AVAILABLE AND NOT CERTAINLY AT THIS VALUE: CONF. CALL.ABBVIE CEO SAYS BELIEVES IT IS HIGHLY UNLIKELY THERE WILL BE A BOTOX BIOSIMILAR FOR A LONG TIME.ABBVIE CEO SAYS FEELS COMFORTABLE WITH RISK RELATED TO ALLERGAN'S OPIOID EXPOSURE.ABBVIE CEO SAYS ALLERGAN BREAKUP FEE IS 1% FOR ALLERGAN, 2% FOR ABBVIE : CONF. CALL.ABBVIE EXECUTIVE SAYS NOT BUILDING IN A LARGE CONTRIBUTION FROM ALLERGAN'S PIPELINE INTO ITS PROJECTIONS.  Full Article

Abbvie To Acquire Allergan For $63 Bln
Tuesday, 25 Jun 2019 

June 25 (Reuters) - AbbVie Inc ::ABBVIE TO ACQUIRE ALLERGAN IN TRANSFORMATIVE MOVE FOR BOTH COMPANIES.TRANSACTION EQUITY VALUE OF APPROXIMATELY $63 BILLION.ALLERGAN SHAREHOLDERS WILL RECEIVE 0.8660 ABBVIE SHARES AND $120.30 IN CASH FOR EACH ALLERGAN SHARE, FOR A TOTAL CONSIDERATION OF $188.24 PER ALLERGAN SHARE.UPON COMPLETION OF TRANSACTION, ABBVIE WILL CONTINUE TO BE INCORPORATED IN DELAWARE AS ABBVIE INC.DEAL IS EXPECTED TO BE 10% ACCRETIVE TO ADJUSTED EARNINGS PER SHARE OVER FIRST FULL YEAR FOLLOWING CLOSE OF TRANSACTION.ABBVIE WILL CONTINUE TO BE LED BY RICHARD A. GONZALEZ AS CHAIRMAN AND CHIEF EXECUTIVE OFFICER.EXPECTED TO GENERATE SIGNIFICANT ANNUAL OPERATING CASH FLOW, WHICH WILL SUPPORT A DEBT REDUCTION TARGET OF $15 TO $18 BILLION BEFORE END OF 2021.ABBVIE ANTICIPATES THAT ACQUISITION WILL PROVIDE ANNUAL PRE-TAX SYNERGIES AND OTHER COST REDUCTIONS OF AT LEAST $2 BILLION IN YEAR THREE.ABBVIE WILL CONTINUE TO BE INCORPORATED IN DELAWARE AS ABBVIE INC. AND HAVE ITS PRINCIPAL EXECUTIVE OFFICES IN NORTH CHICAGO, ILL.2 MEMBERS OF ALLERGAN'S BOARD, INCLUDING CHAIRMAN AND CHIEF EXECUTIVE OFFICER, BRENT SAUNDERS, WILL JOIN ABBVIE'S BOARD UPON CLOSE OF DEAL.COMBINED CO WILL PRODUCE ROBUST CASH FLOW TO SUPPORT CONTINUED DIVIDEND GROWTH, FURTHER INVESTMENT IN PIPELINE AND REDUCTION OF DEBT LEVELS.AFTER DEAL CLOSE, CO'S SHAREHOLDERS TO OWN ABOUT 83% OF CO AND ALLERGAN SHAREHOLDERS WILL OWN ABOUT 17% OF ABBVIE.  Full Article

Abbvie Nears Deal To Buy Allergan For More Than $60 Bln - WSJ
Tuesday, 25 Jun 2019 

June 25 (Reuters) - :ABBVIE NEARS DEAL TO BUY ALLERGAN FOR MORE THAN $60 BILLION - WSJ.ABBVIE'S ALLERGAN TAKEOVER, WORTH $188 A SHARE IN CASH AND STOCK, IS EXPECTED TO BE ANNOUNCED LATER TUESDAY - WSJ, CITING SOURCES.  Full Article

Allergan Receives FDA Clearance For Cooltone Device
Monday, 24 Jun 2019 

June 24 (Reuters) - Allergan plc ::ALLERGAN RECEIVES FDA CLEARANCE FOR COOLTONE™ DEVICE.ALLERGAN PLC - ALLERGAN IS NOW TAKING ORDERS FOR COOLTONE DEVICE, AND FIRST UNITS WILL SHIP EARLY IN Q4 OF THIS YEAR..ALLERGAN - COOLTONE DEVICE GOT FDA CLEARANCE FOR IMPROVEMENT OF ABDOMINAL TONE, STRENGTHENING OF ABDOMINAL MUSCLES, AND DEVELOPMENT FOR FIRMER ABDOMEN.  Full Article

Ironwood And Allergan Report Positive Topline Data From Phase Iiib Trial Of Linzess
Wednesday, 19 Jun 2019 

June 18 (Reuters) - Allergan plc ::IRONWOOD AND ALLERGAN REPORT POSITIVE TOPLINE DATA FROM PHASE IIIB TRIAL OF LINZESS® (LINACLOTIDE) IN ADULTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C).ALLERGAN PLC - PHASE IIIB STUDY MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE.ALLERGAN PLC - PHASE IIIB STUDY DEMONSTRATED LINACLOTIDE IMPROVED OVERALL ABDOMINAL SYMPTOMS OF BLOATING, PAIN AND DISCOMFORT IN ADULTS WITH IBS-C.ALLERGAN PLC - LINACLOTIDE WAS WELL-TOLERATED IN THIS PHASE IIIB STUDY, WITH MOST COMMONLY REPORTED ADVERSE EVENT BEING DIARRHEA.  Full Article

FDA Approves Amgen And Allergan's KANJINTI
Friday, 14 Jun 2019 

June 13 (Reuters) - Allergan plc ::FDA APPROVES AMGEN AND ALLERGAN'S KANJINTI™ (TRASTUZUMAB-ANNS), A BIOSIMILAR TO HERCEPTIN® (TRASTUZUMAB).ALLERGAN PLC - U.S. FDA HAS APPROVED KANJINTI™ (TRASTUZUMAB-ANNS) FOR ALL APPROVED INDICATIONS OF REFERENCE PRODUCT, HERCEPTIN(®).  Full Article

Allergan To Present Vraylar Data At The American Psychiatric Association 2019 Annual Meeting
Wednesday, 15 May 2019 

May 15 (Reuters) - Allergan plc ::ALLERGAN TO PRESENT VRAYLAR® (CARIPRAZINE) DATA AT THE AMERICAN PSYCHIATRIC ASSOCIATION (APA) 2019 ANNUAL MEETING HIGHLIGHTING CONTINUED COMMITMENT TO MENTAL HEALTH.ALLERGAN - FDA ACTION ON SUPPLEMENTAL NEW DRUG APPLICATION FOR VRAYLAR FOR TREATMENT OF BIPOLAR DEPRESSION IS EXPECTED IN FIRST HALF THIS YEAR.  Full Article

Allergan CEO Says Sense Of Urgency To Create Value Is High
Tuesday, 7 May 2019 

May 7 (Reuters) - Allergan plc ::ALLERGAN CEO SAYS SENSE OF URGENCY TO CREATE VALUE IS HIGH; BOARD IS ACTIVELY REVIEWING ALTERNATIVE AVENUES TO UNLOCK VALUE IN NEAR TERM: CONF. CALL.ALLERGAN SAYS Q1 SALES OF COOLSCULPTING IMPACTED BY CONSUMER DEMAND AND REDUCTION IN SYSTEM SALES IN THE US: CONF. CALL.ALLERGAN ESTIMATES ONLY 2 PERCENT OF PATIENTS ON NEW CLASS OF MIGRAINE DRUGS WERE SWITCHED FROM BOTOX AND COMBINATION USE IS LIMITED: CONF. CALL.ALLERGAN SAYS ANTICIPATING MID-MAY LOSS OF EXCLUSIVITY FOR RESTASIS.ALLERGAN CEO SAYS BOARD REMAINS OPEN-MINDED ABOUT SPLIT OF CO IF IT IS SOMETHING THAT CREATES LONG-TERM VALUE.  Full Article

Allergan PLC Posts Q1 GAAP Loss Per Share $7.25
Tuesday, 7 May 2019 

May 7 (Reuters) - Allergan plc ::ALLERGAN REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 GAAP LOSS PER SHARE $7.25.Q1 EARNINGS PER SHARE ESTIMATE $3.55 -- REFINITIV IBES DATA.Q1 NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $3.79.RAISES FULL-YEAR 2019 GUIDANCE FOR NET REVENUE AND NON-GAAP PERFORMANCE NET INCOME PER SHARE.QTRLY TOTAL NET REVENUE $ 3,597.1 MILLION VERSUS $3,672.1 MILLION REPORTED LAST YEAR.Q1 GAAP NET REVENUE DRIVEN BY GROWTH IN TOP PROMOTED PRODUCTS INCLUDING BOTOX , VRAYLAR , JUVÉDERM COLLECTION OF FILLERS AND LO LOESTRIN.RESTASIS NET REVENUES IN Q1 OF 2019 WERE $231.7 MILLION, A DECREASE OF 9.4 PERCENT VERSUS PRIOR YEAR QUARTER.ALLERGAN RECORDED A GOODWILL IMPAIRMENT OF $2.47 BILLION IN THREE MONTHS ENDED MARCH 31, 2019.SEES FY GAAP REVENUE $15.125 BILLION - $15.425 BILLION.SEES FY NON GAAP REVENUE $15.100 BILLION - $15.400 BILLION.SEES FY GAAP LOSS PER SHARE GREATER THAN $5.70.SEES Q2 TOTAL NET REVENUES $3.875 BILLION - $4.025 BILLION.SEES Q2 NET INCOME PER SHARE $0.50 - $0.70.SEES FY NON GAAP EARNINGS PER SHARE GREATER THAN $16.55.FY2019 EARNINGS PER SHARE VIEW $16.44, REVENUE VIEW $15.20 BILLION -- REFINITIV IBES DATA.Q1 REVENUE VIEW $3.54 BILLION -- REFINITIV IBES DATA.SEES Q2 NON-GAAP NET INCOME PER SHARE $4.20 - $4.40.SEES Q2 NON-GAAP REVENUE $3.850 BILLION- $4.000 BILLION.QTRLY BOTOX NET REVENUE $868.4 MILLION VERSUS $817.3 MILLION.Q2 EARNINGS PER SHARE VIEW $4.20, REVENUE VIEW $3.87 BILLION -- REFINITIV IBES DATA.  Full Article

Photo

U.S. dominates second quarter global M&A as mega deals roll on

NEW YORK/LONDON Mega deals set the pace for mergers and acquisitions (M&A) globally in the second quarter of 2019, as large U.S. companies defied trade row jitters and seized on strong equity and debt capital markets to agree on transformative combinations.